Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adaptive Biotechnologies Corp Logo
Maps immune genetics for blood cancer diagnostics and drug discovery partnerships.
United States of America
ADPT
Adeia Inc. Logo
Invents and licenses foundational IP for the media and semiconductor industries.
United States of America
ADEA
Aditxt, Inc. Logo
Acquires and develops biotech for autoimmunity, cancer detection, and neuro diagnostics.
United States of America
ADTX
Advanced Biomed Inc. Logo
Develops microfluidic biochips for rapid, affordable liquid biopsy in precision oncology.
United States of America
ADVB
AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
Ainos, Inc. Logo
Develops AI-powered 'SmellTech' diagnostics and immune therapies for point-of-care testing.
United States of America
AIMD
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Aladdin Healthcare Technologies SE Logo
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany
NMI
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS

Talk to a Data Expert

Have a question? We'll get back to you promptly.